About Clinical and Molecular Allergy

What is Clinical and Molecular Allergy?

Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable.

At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response (inflammatory cell function, elaboration of mediators and cell-cell signaling). The journal also considers studies of novel diagnostic and therapeutic approaches to allergic (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. These include but are not limited to the use of monoclonal antibodies, immunomodulatory (intravenous immunoglobulin and biological response modifiers) and cytokine- or gene-based therapies.

Content overview

Clinical and Molecular Allergy considers the following types of articles:

• Research - reports of data from original clinical or basic research that provide an insight into the mechanisms governing the allergic response.
• Case reports - reports of clinical cases that provide molecular insights into and/or mechanisms governing common or rare diseases.
• Reviews - comprehensive, authoritative descriptions of any subject within the journal's scope; including timely topics in allergy that will cover the clinical as well as the molecular, etiopathogenic aspects of clinical allergic disease.
• Commentaries - short, focused and opinionated articles on current issues regarding the molecular pathogenesis and management of allergic disease.

Peer review policies

Peer review in Clinical and Molecular Allergy is designed to ensure that published articles are scientifically sound. Submitted manuscripts will be sent to two external experts for evaluation for scientific significance and validity. Peer reviewers will have three possible options for each manuscript: accept, accept with revision, and reject. Peer reviewers are asked to justify their decision. Based on the critiques of the reviewers, the authors may choose to revise their manuscript and resubmit it for an additional review. Clinical and Molecular Allergy allows authors a maximum of two revisions of a manuscript.

Edited by David S Chi and Guha Krishnaswamy, Clinical and Molecular Allergy is supported by an international Editorial Board.

Publishing in Clinical and Molecular Allergy

All articles will be listed in PubMed immediately upon acceptance (after peer review), and will be covered by PubMed Central, CAS and Embase.

Articles in Clinical and Molecular Allergy should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number.

The following citation:

Clin Mol Allergy 2004, 2:1

refers to article 1 from volume 2 of the journal.

As an online journal, Clinical and Molecular Allergy does not have issue numbers. Each volume corresponds to a calendar year.

To keep up to date with the latest articles from Clinical and Molecular Allergy, why not register to receive alerts? Registration also enables you to customise your subject areas of interest, store your searches, and submit your manuscripts.

Submission of manuscripts

Manuscripts should be submitted electronically to Clinical and Molecular Allergy using the online submission system. Full details of how to submit a manuscript are given in the instructions for authors.

General journal policies

Clinical and Molecular Allergy is published  by BioMed Central, an independent publisher committed to ensuring peer-reviewed biomedical research is Open Access. That means it is freely and universally accessible online, it is archived in at least one internationally recognised free access repository, and its authors retain copyright, allowing anyone to reproduce or disseminate articles, according to the BioMed Central copyright and licence agreement. Clinical and Molecular Allergy however, has taken this further by making all its content Open Access.

Clinical and Molecular Allergy's articles are archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also at INIST in France and in e-Depot, the National Library of the Netherlands' digital archive of all electronic publications. The journal is also participating in the British Library's e-journals pilot project, and plans to deposit copies of all articles with the British Library.

BioMed Central is working closely with the Thomson Reuters (ISI) to ensure that citation analysis of articles published in Clinical and Molecular Allergy will be available.

Clinical and Molecular Allergy is able to deliver summaries of frequently updated content via Really Simple Syndication (RSS) feeds. These are accessible via the orange "XML" button at the top of the list of recent articles or the list of most accessed articles. For more information about RSS feeds see our publisher's website.

For further information about general policies please see the instructions for authors.